10-K/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-K/A

(Amendment No. 1)

(Mark One)

[X]   ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2011

OR

[   ]   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _________ to _________

Commission file number 033-76414

ARIAD Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation or organization) 22-3106987 (I.R.S. Employer Identification No.)

26 Landsdowne Street, Cambridge, Massachusetts 02139-4234

(Address of principal executive offices)                                  (Zip Code)

Registrant’s telephone number, including area code: (617) 494-0400

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Name of each exchange on which registered
Common Stock, $.001 par value	The NASDAQ Global Select Market

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes  [ X ]     No  [    ]

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act.

Yes  [    ]     No  [ X ]

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  [ X ]     No  [    ]

1

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes [ X ]    No [    ]

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. [ X ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer [ X ]    Accelerated filer [    ]

Non-accelerated filer [    ] (Do not check if a smaller reporting company)         Smaller reporting company  [    ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes  [    ]     No  [ X ]

The aggregate market value of the registrant’s common stock held by nonaffiliates of the registrant (without admitting that any person whose shares are not included in such calculation is an affiliate), computed by reference to the price at which the common stock was last sold, as of the last business day of the registrant’s most recently completed second fiscal quarter was approximately $1,220,167,480.

As of February 15, 2012, the registrant had 158,929,544 shares of common stock outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

The following documents (or parts thereof) are incorporated by reference into the following parts of this Form 10-K:  Certain information required in Part III of this Annual Report on Form 10-K is incorporated from the Registrant’s Definitive Proxy Statement for the 2012 Annual Meeting of Stockholders.

EXPLANATORY NOTE

The sole purpose of this Amendment No. 1 to the Annual Report on Form 10-K of ARIAD Pharmaceuticals, Inc. (the “Company”) for the fiscal year ended December 31, 2011, filed with the Securities and Exchange Commission on February 29, 2012 (the “Form 10-K”), is to furnish the Interactive Data Files on Exhibit 101.

As permitted by Rule 405(a)(2)(ii) of Regulation S-T, the Company is furnishing the Interactive Data Files on Exhibit 101 by amendment within 30 days of the original filing date of the Form 10-K.  No other changes have been made to the Form 10-K, and this Amendment has not been updated to reflect events occurring subsequent to the filing of the Form 10-K.

Pursuant to Rule 406T of Regulation S-T, the Interactive Data Files on Exhibit 101 are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and are otherwise not subject to liability under those sections.

2

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Act of 1934, the registrant has duly caused this Amendment No. 1 to its Annual Report on Form 10-K/A to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge and Commonwealth of Massachusetts on the 30th day of March, 2012.

ARIAD PHARMACEUTICALS, INC.
By:	/s/ Edward M. Fitzgerald
Name:	Edward M. Fitzgerald
Title:	Executive Vice President, Chief Financial Officer and Treasurer (Principal Financial Officer and Principal Accounting Officer)

3

ARIAD Pharmaceuticals, Inc.

Form 10-K for the year ended December 31, 2011

Exhibit List

Exhibit Number	Exhibit Description	Filed with this Report	Incorporated by Reference herein from Form or Schedule	Filing Date	SEC File/ Reg. Number
2.1	Certificate of Ownership and Merger of ARIAD Corporation into ARIAD Pharmaceuticals, Inc. dated December 28, 2011	**
3.1	Certificate of Incorporation of ARIAD Pharmaceuticals, Inc., as amended		10-Q (Exhibit 3.1)	05/10/10	000-21696
3.2	Amended and Restated By-laws of ARIAD Pharmaceuticals, Inc.		8-K (Exhibit 3.1)	08/27/09	000-21696
4.1	Specimen common stock certificate of ARIAD Pharmaceuticals, Inc.	**
4.2	Form of Warrant to Purchase Common Stock dated February 25, 2009		8-K (Exhibit 10.2)	02/20/09	000-21696

Leases and Credit Agreements
10.1	.1	Lease Agreement, dated January 8, 1992, between ARIAD Pharmaceuticals, Inc. and Forest City Cambridge, Inc.		10 (Exhibit 10.1)	04/30/93	000-21696
	.2	Eighth Amendment to Lease dated October 30, 2006		10-K (Exhibit 10.57)	03/14/07	000-21696
	.3	Ninth Amendment to Lease dated May 20, 2011, between ARIAD Corporation and UP 26 Landsdowne LLC		10-Q (Exhibit 10.1)	08/09/11	000-21696
	.4	Assignment and Assumption dated December 31, 2011, by and between ARIAD Corporation and ARIAD Pharmaceuticals, Inc. (for lease at 26 Landsdowne Street)	**
10.2	.1	Credit Agreement, dated as of March 12, 2003, by and among ARIAD Pharmaceuticals, Inc., ARIAD Corporation and ARIAD Gene Therapeutics, Inc. and Citizens Bank of Massachusetts		10-Q (Exhibit 10.1)	05/13/03	000-21696
	.2	Amendment No. 1 to Credit Agreement, dated as of December 31, 2003		10-K (Exhibit 10.57)	03/02/04	000-21696

4

	.3	Amendment No. 2 to Credit Agreement dated as of December 31, 2004		10-K (Exhibit 10.52)	02/18/05	000-21696
	.4	Amendment No. 3 to Credit Agreement, dated as of March 26, 2008, by and among ARIAD Pharmaceuticals, Inc., ARIAD Corporation and ARIAD Gene Therapeutics, Inc. and RBS Citizens, National Association, successor by merger to Citizens Bank of Massachusetts		8-K (Exhibit 10.2.4)	03/27/08	000-21696
	.5	Waiver and Amendment No. 4 to Credit Agreement dated as of June 19, 2009, by and among ARIAD Pharmaceuticals, Inc., ARIAD Corporation and RBS Citizens, National Association		10-Q (Exhibit 10.3)	08/10/09	000-21696
	.6	Waiver and Amendment No. 5 to Credit Agreement dated as of December 14, 2009		10-K (Exhibit 10.2.6)	03/16/10	000-21696
	.7	Amendment No. 6 to Credit Agreement, dated as of January 6, 2011		8-K (Exhibit 10.2.7)	01/12/11	000-21696
	.8	Amendment No. 7 to Credit Agreement, dated as of December 28, 2011, by and among ARIAD Pharmaceuticals, Inc., ARIAD Corporation and RBS Citizens, National Association	**
10.3		Security Agreement - All Assets, dated as of March 12, 2003, by and between ARIAD Pharmaceuticals, Inc. and Citizens Bank of Massachusetts		10-Q (Exhibit 10.3)	05/13/03	000-21696
10.4		Security Agreement - All Assets, dated as of March 12, 2003, by and between ARIAD Corporation and Citizens Bank of Massachusetts		10-Q (Exhibit 10.4)	05/13/03	000-21696
10.5		Third Amended and Restated Term Note, dated March 26, 2008, issued by ARIAD Pharmaceuticals, Inc., ARIAD Corporation and ARIAD Gene Therapeutics, Inc. to RBS Citizens, National Association, successor by merger to Citizens Bank of Massachusetts		8-K (Exhibit 10.2.4)	03/27/08	000-21696

5

Agreements with Respect to Collaborations, Licenses, Research and Development
10.6	Amended and Restated Agreement, dated as of December 12, 1997, between The Board of Trustees of The Leland Stanford Junior University and ARIAD Gene Therapeutics, Inc.*	10-K (Exhibit 10.14)	03/10/98	000-21696
10.7	Revised and Restated Research and Development Agreement, dated as of March 15, 2002, by and between ARIAD Pharmaceuticals, Inc. and ARIAD Corporation	10-K (Exhibit 10.53)	03/22/02	000-21696
10.8	License Agreement, effective January 26, 2005, by and between ARIAD Pharmaceuticals, Inc. and Medinol Ltd.*	10-Q (Exhibit 10.1)	05/10/05	000-21696
10.9	Supply Agreement, entered into as of January 26, 2005, by and between ARIAD Pharmaceuticals, Inc. and Medinol Ltd.*	10-Q (Exhibit 10.2)	05/10/05	000-21696
10.10	License Agreement, dated October 9, 2007, among ARIAD Pharmaceuticals, Inc., ARIAD Gene Therapeutics, Inc. and ICON Medical Corp.*	10-K (Exhibit 10.13)	03/16/10	000-21696
10.11	Amended and Restated Collaboration and Exclusive License Agreement, dated May 4, 2010, between ARIAD Pharmaceuticals, Inc. and Merck, Sharpe & Dohme Corp.*	10-Q (Exhibit 10.1)	08/09/10	000-21696

Agreements with Executive Officers and Directors
10.12	Amended and Restated Executive Employment Agreement, dated April 30, 2010, between ARIAD Pharmaceuticals, Inc. and Harvey J. Berger, M.D. +	8-K (Exhibit 10.1)	05/03/10	000-21696
10.13	Amended and Restated Executive Employment Agreement, dated May 15, 2010, between ARIAD Pharmaceuticals, Inc. and David L. Berstein, Esq.+	10-Q (Exhibit 10.4)	08/09/10	000-21696
10.14	Amended and Restated Executive Employment Agreement, dated May 15, 2010, between ARIAD Pharmaceuticals, Inc. and Daniel M. Bollag, Ph.D.+	10-Q (Exhibit 10.5)	08/09/10	000-21696
10.15	Amended and Restated Executive Employment Agreement, dated May 15, 2010, between ARIAD Pharmaceuticals, Inc. and Timothy P. Clackson, Ph.D.+	10-Q (Exhibit 10.6)	08/09/10	000-21696

6

10.16		Amended and Restated Executive Employment Agreement, dated May 15, 2010, between ARIAD Pharmaceuticals, Inc. and Pierre F. Dodion, M.D., M.B.A.+		10-Q (Exhibit 10.7)	08/09/10	000-21696
10.17		Executive Employment Agreement, dated September 3, 2011, by and between ARIAD Pharmaceuticals, Inc. and Martin J. Duvall+		10-Q (Exhibit 10.1)	11/07/11	000-21696
10.18		Amended and Restated Executive Employment Agreement, dated May 15, 2010, between ARIAD Pharmaceuticals, Inc. and Edward M. Fitzgerald+		10-Q (Exhibit 10.8)	08/09/10	000-21696
10.19		Amended and Restated Executive Employment Agreement, dated May 1, 2010, by and between ARIAD Pharmaceuticals, Inc. and Frank G. Haluska, M.D., Ph.D.+		10-Q (Exhibit 10.9)	08/09/10	000-21696
10.20		Amended and Restated Executive Employment Agreement, dated May 15, 2010, between ARIAD Pharmaceuticals, Inc. and Raymond T. Keane, Esq.+		10-Q (Exhibit 10.10)	08/09/10	000-21696
10.21	.1	ARIAD Pharmaceuticals, Inc. 1997 Executive Compensation Plan+		10-K (Exhibit 10.41)	03/10/98	000-21696
	.2	Amendment to ARIAD Pharmaceuticals, Inc. 1997 Executive Compensation Plan+		10-Q (Exhibit 10.2)	11/09/05	000-21696
10.22		ARIAD Pharmaceuticals, Inc. 2005 Executive Compensation Plan (as amended and restated effective October 1, 2008)+		10-K (Exhibit 10.31)	03/16/09	000-21696
10.23		Director Compensation Arrangements+	**
10.24		Form of Indemnity Agreement between ARIAD Pharmaceuticals, Inc. and its directors and officers+		10-K (Exhibit 10.33)	03/16/09	000-21696

Equity Compensation Plans
10.25	.1	ARIAD Pharmaceuticals, Inc. 1991 Stock Option Plan for Employees and Consultants, as amended+	10-K (Exhibit 10.13)	03/31/95	000-21696
	.2	Amendment to the 1991 Stock Option Plan for Employees and Consultants+	10-Q (Exhibit 10.36)	08/12/97	000-21696
10.26		ARIAD Pharmaceuticals, Inc. 1991 Stock Option Plan for Directors+	10 (Exhibit 10.15)	04/30/93	000-21696

7

10.27	.1	ARIAD Pharmaceuticals, Inc. 1994 Stock Option Plan for Non-Employee Directors+		10-K (Exhibit 10.24)	03/31/95	000-21696
	.2	Amendment to the 1994 Stock Option Plan for Non-Employee Directors.+		10-Q (Exhibit 10.37)	08/12/97	000-21696
10.28		Amended and Restated ARIAD Pharmaceuticals, Inc. 1997 Employee Stock Purchase Plan+		Def 14A (Appendix A)	04/30/09	000-21696
10.29		ARIAD Pharmaceuticals, Inc. 2001 Stock Plan, as amended and restated+		10-Q (Exhibit 10.3)	11/09/05	000-21696
10.30	.1	ARIAD Pharmaceuticals, Inc. 2006 Long-Term Incentive Plan, as amended+		Def 14A (Appendix A)	05/02/11	000-21696
	.2	Form of Stock Option Certificate under the ARIAD Pharmaceuticals, Inc. 2006 Long-Term Incentive Plan+	**
	.3	Form of Stock Grant Certificate under the ARIAD Pharmaceuticals, Inc. 2006 Long-Term Incentive Plan+	**
	.4	Form of Restricted Stock Unit Certificate under the ARIAD Pharmaceuticals, Inc. 2006 Long-Term Incentive Plan+	**
	.5	Form of Restricted Stock Grant Certificate under the ARIAD Pharmaceuticals, Inc. 2006 Long-Term Incentive Plan+	**
21.1		Subsidiaries of ARIAD Pharmaceuticals, Inc.	**
23.1		Consent of Deloitte & Touche LLP	**
31.1		Certification of the Chief Executive Officer	**
31.2		Certification of the Chief Financial Officer	**
32.1		Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	**

8

101 The following materials from ARIAD Pharmaceutical, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2011, formatted in XBRL (eXtensible Business Reporting Language): (i) Consolidated Balance Sheets, (ii) Consolidated Income Statements, (iii) Consolidated Statements of Stockholders’ Equity and Comprehensive Income, (iv) Consolidated Statements of Cash Flows, and (v) Notes to Consolidated Financial Statements.*** X

(+)	Management contract or compensatory plan or arrangement.
(*)	Confidential treatment has been granted by the Securities and Exchange Commission as to certain portions.

(**)	These exhibits were previously included with the Company’s Annual Report on Form 10-K for the period ended December 31, 2011, filed with the Securities and Exchange Commission on February 29, 2012.
(***)	Pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933 or Section 18 of the Securities Exchange Act of 1934 and otherwise are not subject to liability under these sections.

9

XML

Executive Compensation Plan (Detail) (USD $)	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Schedule Of Executive Compensation Plan [Line Items]
Deferred executive compensation plan, grant date value of awards	$ 1,600,000	$ 1,800,000	$ 1,100,000
Deferred executive compensation plan, net expense	1,719,000	1,477,000	1,134,000
Deferred executive compensation plan, estimated future expense for unvested awards year one	1,500,000
Deferred executive compensation plan, estimated future expense for unvested awards year two	544,000
Deferred executive compensation plan, estimated future expense for unvested awards year three	$ 136,000

XML

Potentially Dilutive Securities Excluded in the Computation of Net Income (Loss) Per Share (Detail) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	15,972	15,416	19,957
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	7,381	5,852	7,684
Restricted Stock and Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	2,785		1,489
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	5,806	9,564	10,784

XML

The Weighted-Average Assumptions of Fair Value of Options Granted (Detail) (USD $)	12 Months Ended
	Dec. 31, 2011 Year	Dec. 31, 2010 Year	Dec. 31, 2009 Year
Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]
Expected life of options granted (in years)	7.48	6.75	7.04
Expected volatility	74.77%	78.54%	70.68%
Risk-free rate	2.53%	2.57%	2.75%
Expected dividends	$ 0	$ 0	$ 0

XML

Reconciliation of the Federal Statutory Corporate Income Tax Rate to the Effective Income Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Reconciliation of Provision of Income Taxes [Line Items]
Statutory federal income tax rate	(35.00%)	35.00%	(35.00%)
State income tax rate, net of federal benefit	(4.00%)	5.00%	(6.00%)
Revaluation of warrant liability	13.00%	8.00%	3.00%
Other permanent differences		1.00%	1.00%
Change in valuation allowance	26.00%	(49.00%)	37.00%
Effective tax rate	0.00%	0.00%	0.00%

XML

Total Compensation Cost from Share-Based Payments (Detail) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation cost	$ 7,675	$ 4,836	$ 4,355
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation cost	3,782	2,444	2,123
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation cost	3,893	2,392	2,232
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation cost	2,893	1,879	3,068
Stock and Stock Units Grants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation cost	4,601	2,834	1,096
Employee Stock Purchase Plans [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation cost	$ 181	$ 123	$ 191

XML

Property and Equipment, Net (Schedule of Assets Under Capital Leases) (Detail) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2011	Dec. 31, 2010
Property, Plant and Equipment [Line Items]
Equipment and furniture	$ 17,032	$ 15,675
Less accumulated depreciation and amortization	(33,372)	(30,728)
Property, plant and equipment, net	6,611	7,037
Assets Held under Capital Leases [Member]
Property, Plant and Equipment [Line Items]
Equipment and furniture	392	420
Less accumulated depreciation and amortization	(257)	(172)
Property, plant and equipment, net	$ 135	$ 248

XML

Estimated Net Operating Loss Carryforwards And Research and Development Credit Carryforwards for Federal and State Tax (Detail) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2011
Operating Loss Carryforwards and Research and Development Credit Carryforwards [Line Items]
Loss carryforward, federal	457,459
Loss carryforward, state	79,197
Research and development credit carryforwards, federal	18,448
Research and development credit carryforwards, state	7,588
Federal [Member]
Operating Loss Carryforwards and Research and Development Credit Carryforwards [Line Items]
Operating loss expiration date	2012 through 2031
State [Member]
Operating Loss Carryforwards and Research and Development Credit Carryforwards [Line Items]
Operating loss expiration date	2012 through 2016
Research and Development Credit Carryforwards [Member] | Federal [Member]
Operating Loss Carryforwards and Research and Development Credit Carryforwards [Line Items]
Research and development credit carryforwards date	2012 through 2031
Research and Development Credit Carryforwards [Member] | State [Member]
Operating Loss Carryforwards and Research and Development Credit Carryforwards [Line Items]
Research and development credit carryforwards date	2012 through 2026

XML

Fair Value of Financial Instruments (Tables)

12 Months Ended

Dec. 31, 2011

Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following table presents information about the Company’s assets and liabilities as of December 31, 2011 and 2010 that are measured at fair value on a recurring basis and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value:

	December 31, 2011
In thousands	Total		Level 1		Level 2		Level 3
Warrant liability	$	58,639	$	---	$	58,639	$	---

	December 31, 2010
In thousands	Total		Level 1		Level 2		Level 3
Warrant liability	$	28,815	$	---	$	---	$	28,815

Fair Value of the Warrants Determined Using the Black-Scholes Option Valuation Model

The fair value of the warrants is determined using the Black-Scholes option valuation model, applying the following inputs as of December 31, 2011, 2010 and 2009:

	2011			2010			2009
Market price per share of the Company’s common stock	$	12.25		$	5.10		$	2.28
Risk-free interest rate		0.015	%		0.34	%		1.23	%
Expected term (years)		0.2			1.2			2.2
Dividend yield		---			---			---
Volatility		59.9	%		54.0	%		79.0	%

Changes in the Fair Value of Warrant Liability

The changes in the fair value of the warrant liability for the years ended December 31, 2011, 2010 and 2009 were as follows:

In thousands	2011			2010			2009
Balance, beginning of year	$	28,815		$	11,363		$	---
Issuance of warrants		---			---			3,559
Revaluation of warrants		46,715			19,532			7,804
Exercise of warrants		(16,891	)		(2,080	)		---
Balance, end of year	$	58,639		$	28,815		$	11,363

XML

Summary of Stock Options Outstanding (Detail) (USD $) In Thousands, except Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2011 Year	Dec. 31, 2010
Options Exercisable
Number of options	5,055,872
Weighted average exercise price per share	$ 4.84
Aggregate intrinsic value	$ 37,468
Weighted average remaining contractual term	4.07
Options vested and expected to vest
Number of options	7,066,555
Weighted average exercise price per share	$ 5.21
Aggregate intrinsic value	49,717
Weighted average remaining contractual term	5.38
Options Outstanding
Number of options	7,381,329	7,177,191
Weighted average exercise price per share	$ 5.22	$ 4.42
Aggregate intrinsic value	$ 51,878
Weighted average remaining contractual term	5.52

XML

Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) (Warrant Liability [Member], USD $) In Thousands, unless otherwise specified	Dec. 31, 2011	Dec. 31, 2010
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liabilities	$ 58,639	$ 28,815
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liabilities	58,639
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liabilities		$ 28,815

XML

Long-term Debt and Capital Lease Obligations (Narrative) (Detail) (USD $)	12 Months Ended		12 Months Ended	1 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2010 Before Amendment [Member]	Jan. 31, 2011 After Amendment [Member]
Debt Instrument [Line Items]
Bank term loan	$ 12,600,000	$ 9,625,000	$ 9,625,000	$ 14,000,000
Bank term loan, maturity date			Mar. 31, 2013	Dec. 31, 2015
Bank term loan, quarterly repayment as a percent of the principal amount				2.50%
Bank term loan, repayment in the final quarter as a percent of the principal amount				8.75%
Bank term loan, interest rate over and above LIBOR, minimum	1.25%
Bank term loan, interest rate over and above LIBOR, maximum	2.25%
Bank term loan, effective interest rate	1.79%
Bank term loan, required minimum in unrestricted cash, cash equivalents and investments	$ 15,000,000
Capital leases, term in years	3 years
Capital leases, minimum effective interest rate	5.60%
Capital leases, maximum effective interest rate	7.20%

XML

Stock and Stock Unit Activity under Stock Plans (Detail) (USD $)	12 Months Ended
	Dec. 31, 2011
Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock and Stock Units [Line Items]
Outstanding, beginning balance	2,779,300
Granted	1,255,681
Forfeited	115,632
Vested or restrictions lapsed	1,134,323
Outstanding, ending balance	2,785,026
Outstanding, beginning balance	$ 2.83
Granted	$ 7.43
Forfeited	$ 4.05
Vested or restrictions lapsed	$ 3.69
Outstanding, ending balance	$ 4.51

XML

Summary of Information About Stock Options (Detail) (USD $) In Thousands, except Per Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average fair value of options granted, per share	$ 5.80	$ 2.43	$ 1.03
Total cash received from exercises of stock options	$ 4,648	$ 418	$ 206
Total intrinsic value of stock options exercised	$ 5,169	$ 331	$ 271

XML

Property and Equipment, Net

12 Months Ended

Dec. 31, 2011

Property and Equipment, Net

3.     Property and Equipment, Net

Property and equipment, net, was comprised of the following at December 31:

In thousands	2011			2010
Leasehold improvements	$	22,252		$	22,090
Construction in progress		699			---
Equipment and furniture		17,032			15,675
		39,983			37,765
Less accumulated depreciation and amortization		(33,372	)		(30,728	)
	$	6,611		$	7,037

Depreciation and amortization expense for the years ended December 31, 2011, 2010 and 2009 was $2.8 million, $3.0 million and $3.2 million, respectively.

The Company leases certain assets under capital leases having terms up to three years.  Assets under capital leases included in property and equipment were as follows at December 31:

In thousands	2011			2010
Equipment and furniture	$	392		$	420
Less accumulated depreciation and amortization		(257	)		(172	)
	$	135		$	248

XML

The Fair Value of the Warrants Determined Using the Black-Scholes Option Valuation Model (Detail) (Warrant Liability [Member], USD $)	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Warrant Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis, Valuation Techniques [Line Items]
Market price per share of the Company's common stock	$ 12.25	$ 5.10	$ 2.28
Risk-free interest rate	0.015%	0.34%	1.23%
Expected term (years)	0.02	1.2	2.2
Dividend yield
Volatility	59.90%	54.00%	79.00%

XML

Nature of Business and Summary of Significant Accounting Policies (Detail) (USD $) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2011 Product Year Segment
Significant Accounting Policies [Line Items]
Number of product candidates under development	3
Property and equipment, useful life minimum	3
Property and equipment, useful life maximum	10
Capitalized costs, amortization period maximum	17
Tax benefit, minimum percentage of likelihood of being realized upon ultimate settlement	50.00%
Deferred executive compensation plan, vesting period	4 years
Accrued rent	$ 1.7
Number of operating segments	1

XML

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2011

Reconciliation of the Federal Statutory Corporate Income Tax Rate to the Effective Income Tax Rate

A reconciliation of the federal statutory corporate income tax rate to the effective income tax rate for the years ended December 31, 2011, 2010 and 2009 is as follows:

	2011		2010		2009
Statutory federal income tax rate	(35	)%	35	%	(35	)%
State income tax rate, net of federal benefit	(4	)	5		(6	)
Revaluation of warrant liability	13		8		3
Other permanent differences	---		1		1
Change in valuation allowance	26		(49	)	37
Effective tax rate	0	%	0	%	0	%

Components of Deferred Income Taxes

The components of deferred income taxes were as follows at December 31:

In thousands	2011			2010
Deferred tax liabilities:
Intangibles	$	2,385		$	2,813
Deferred tax assets:
Net operating loss carryforwards		161,951			134,065
Federal and state tax credit carryovers		23,380			24,489
Depreciation		4,924			4,837
Stock-based compensation		3,420			3,122
Other		2,158			1,289
Total deferred tax assets		195,833			167,802
Deferred tax assets, net		193,448			164,989
Valuation allowance		(193,448	)		(164,989	)
Total deferred taxes	$	---		$	---

Estimated Net Operating Loss and Research and Development Credit Carryforwards

At December 31, 2011, the Company had available estimated net operating loss carryforwards and research and development credit carryforwards for federal and state tax reporting purposes as follows:

	Amount		Expiring if not utilized
	(in 000s)
Net operating loss carryforwards:
Federal	$	457,459	2012 through 2031
State	$	79,197	2012 through 2016
Research and development credit carryforwards:
Federal	$	18,448	2012 through 2031
State	$	7,588	2012 through 2026

XML

Components of Deferred Income Taxes (Detail) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2011	Dec. 31, 2010
Deferred tax liabilities:
Intangibles	$ 2,385	$ 2,813
Deferred tax assets:
Net operating loss carryforwards	161,951	134,065
Federal and state tax credit carryovers	23,380	24,489
Depreciation	4,924	4,837
Stock-based compensation	3,420	3,122
Other	2,158	1,289
Total deferred tax assets	195,833	167,802
Deferred tax assets, net	193,448	164,989
Valuation allowance	(193,448)	(164,989)
Total deferred taxes

XML

Changes in the Fair Value of Warrant Liability (Detail) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Derivatives, Fair Value [Line Items]
Balance, beginning of year	$ 28,815	$ 11,363
Issuance of warrants			3,559
Revaluation of warrants	46,715	19,532	7,804
Exercise of warrants	(16,891)	(2,080)
Balance, end of year	$ 58,639	$ 28,815	$ 11,363

XML

Collaboration and License Agreements with Merck & Co., Inc. (Detail) (USD $)	12 Months Ended		1 Months Ended	4 Months Ended	35 Months Ended	8 Months Ended	20 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Jul. 31, 2007 Collaborative Arrangement [Member]	May 04, 2010 Collaborative Arrangement [Member]	May 04, 2010 Collaborative Arrangement [Member]	Dec. 31, 2010 License Agreement Terms [Member]	Dec. 31, 2011 License Agreement Terms [Member]	Dec. 31, 2011 License Agreement Terms [Member] Sarcoma [Member]	Dec. 31, 2011 License Agreement Terms [Member] Other Cancer [Member]	Dec. 31, 2011 License Agreement Terms [Member] UNITED STATES Sarcoma [Member]	Dec. 31, 2011 License Agreement Terms [Member] European Union [Member] Sarcoma [Member]	Dec. 31, 2011 License Agreement Terms [Member] JAPAN Sarcoma [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Percentage of global development costs funded by each party in collaboration					50.00%
Proceeds from collaborators			$ 75,000,000	$ 12,800,000	$ 53,500,000
Percentage of costs funded in the license agreement							100.00%
Percentage of co-promotion by the company, maximum							20.00%
Proceeds from license fees						50,000,000
Potential milestone payments associated with the achievement of certain regulatory and sales objectives							514,000,000
Potential additional milestone payments associated with the achievement of certain sales thresholds							200,000,000
Proceeds from regulatory or sales milestone payments								25,000,000
Potential additional milestone payments associated with potential regulatory approvals								40,000,000	249,000,000	25,000,000	10,000,000	5,000,000
Recognition of deferred revenue		111,500,000
Service revenue	$ 111,000	$ 4,520,000

XML

Schedule of Property and Equipment, Net (Detail) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2011	Dec. 31, 2010
Property, Plant and Equipment [Line Items]
Leasehold improvements	$ 22,252	$ 22,090
Construction in progress	699
Equipment and furniture	17,032	15,675
Property, plant and equipment, gross	39,983	37,765
Less accumulated depreciation and amortization	(33,372)	(30,728)
Property, plant and equipment, net	$ 6,611	$ 7,037

XML

Collaboration and License Agreements with Merck & Co., Inc.

12 Months Ended

Dec. 31, 2011

Collaboration and License Agreements with Merck & Co., Inc.

2.     Collaboration and License Agreements with Merck & Co., Inc.

In July 2007, the Company entered into a collaboration agreement with Merck for the joint global development, manufacture and commercialization of ridaforolimus, the Company’s lead product candidate, for use in cancer (the “Collaboration Agreement”).  In May 2010, the Company entered into an amended and restated agreement with Merck for ridaforolimus (the “License Agreement”), which replaced the Collaboration Agreement.  These agreements are described below.

The Collaboration Agreement (July 2007 to May 2010)

Under the terms of the Collaboration Agreement, as in effect until May 4, 2010, Merck and the Company were conducting a broad-based development program for the use of ridaforolimus in multiple types of cancer.  Each party funded 50 percent of global development costs incurred.  Under the terms of the Collaboration Agreement, Merck paid the Company an initial up-front payment of $75 million in July 2007 and milestone payments of $53.5 million through May 4, 2010, based on the achievement of specified clinical and regulatory events.

The Company’s accounting policy for exclusive license arrangements is to recognize revenue when all revenue recognition criteria have been met.  As the Collaboration Agreement included multiple elements, the Company identified the units of accounting and determined the related performance period.  The Company assessed each of the deliverables related to the Collaboration Agreement against the separation criteria for multiple element arrangements and concluded that the license and research and development deliverables constituted one unit of accounting.  This conclusion reflected the nature of the planned research and development services under the terms of the Collaboration Agreement and the ongoing research in multiple cancer indications.  The up-front and milestone payments received were deferred and were being recognized as revenue through 2023, the estimated expiration of the patents related to the underlying technology, which was determined to be the performance period.

Development costs under the Collaboration Agreement were aggregated and split between the Company and Merck in accordance with the terms of the agreement.  The Company’s share of such development costs from inception of the collaboration up to May 4, 2010 was reflected in operating expenses in the Company’s statement of operations.

The License Agreement (May 2010 to present)

Under the terms of the License Agreement, the Company has granted Merck an exclusive license to develop, manufacture and commercialize ridaforolimus in oncology, and Merck has assumed full responsibility for all activities related to the development, manufacture and commercialization of ridaforolimus and funds 100 percent of all ridaforolimus costs incurred after January 1, 2010.  The License Agreement provides that Merck will develop ridaforolimus in multiple oncology indications.  If ridaforolimus receives regulatory approval, Merck will be responsible for selling ridaforolimus worldwide, will record global sales and will pay the Company tiered double-digit royalties on global net sales.  The Company has an option to co-promote ridaforolimus with up to 20 percent of the sales effort in all indications in the United States and, in such case, the Company would be compensated by Merck for its sales efforts.  In the first quarter of 2011, the Company elected to exercise its option to co-promote ridaforolimus for the sarcoma indication, subject to the terms of a co-promotion agreement being negotiated by the Company and Merck.

Under the License Agreement, in 2010 Merck paid the Company an initial up-front fee of $50 million and approximately $12.8 million for its share of costs incurred in the period from January 1, 2010 to May 4, 2010 related to development, manufacture and commercial activities for ridaforolimus in accordance with the cost-sharing provisions of the Collaboration Agreement as in effect during that period.  In addition, Merck has agreed to pay the Company up to $514 million in regulatory and sales milestone payments, based on the successful development of ridaforolimus in multiple potential cancer indications and upon achievement of specified product sales thresholds.  Through December 31, 2011, Merck has paid the Company a $25 million milestone payment for the acceptance of the marketing authorization application in Europe for the sarcoma indication.  Potential additional milestone payments include up to $40 million associated with potential regulatory approvals for the sarcoma indication (consisting of $25 million for marketing approval in the United States, $10 million for approval to sell ridaforolimus in the European Union, including first pricing and reimbursement approval granted by a regulatory authority in any major European country or by the European Medicines Agency (“EMA”), and $5 million for marketing approval of ridaforolimus in Japan), up to $249 million associated with potential regulatory filings and approvals for other cancer indications, and up to $200 million associated with the achievement of certain sales thresholds.  Merck submitted a new drug application for ridaforolimus to the FDA and a marketing authorization application for ridaforolimus to the EMA in the third quarter of 2011, both of which have been accepted for review by these agencies.

Pursuant to the License Agreement, all ridaforolimus activities that had been the responsibility of the Company under the Collaboration Agreement were transitioned to Merck.  Merck agreed to pay the Company for its internal transition services at agreed upon rates and reimburse the Company for all external costs incurred in connection with transition services or research and development activities.  Accordingly, the remaining deliverables of the Company were limited to transition services for which the Company could establish fair value and all deferred revenue was recognized as of May 4, 2010.  Any remaining service revenues are recognized when earned and other revenue recognition criteria are met.

The Company determined that this License Agreement was a new agreement for accounting purposes, as the economic terms and deliverables were materially modified from the prior arrangement.  The Company assessed each of the deliverables related to the License Agreement against the separation criteria for multiple element arrangements and concluded that there are two units of accounting, namely the license and the transition services.  The Company concluded that the license deliverable has stand-alone value, as the nature of the transition services could be provided by other vendors and there was objective and reliable evidence of the fair value of the undelivered transition services.  The Company’s accounting policy for exclusive licenses is to recognize revenue when all revenue recognition criteria are met.  Accordingly, the Company recognized the revenue associated with the delivered elements of the agreement in the second quarter of 2010.

The amounts recognized as license and collaboration revenue for the year ended December 31, 2010 included the following components related to the Merck agreements:

· $50 million up-front payment pursuant to the License Agreement,

· $12.8 million payment received from Merck pursuant to the License Agreement as payment for the Company’s 50 percent share of costs incurred from January 1, 2010 to May 4, 2010, and

· $111.5 million representing the recognition of revenue deferred as of December 31, 2009 under the Company’s accounting for the Collaboration Agreement.

For the year ended December 31, 2011, license and collaboration revenue included the $25 million milestone payment received from Merck for acceptance of the submission of the marketing authorization application for ridaforolimus for the sarcoma indication in Europe.

For the years ended December 31, 2011 and 2010, the Company recorded service revenue of approximately $111,000 and $4.5 million, respectively.  The cost of such services is reflected in operating expenses in the period in which they were incurred.

Merck is required to reimburse the Company for the cost of any services related to ridaforolimus being provided to the Company by outside service providers from May 4, 2010 until completion.  Based on the nature of the arrangement with Merck for management of such services and reimbursement of their costs, reimbursement received from Merck for the cost of such services is reflected as an offset to the related cost and presented on a net basis in operating expenses.  Such services were substantially completed in 2010.  As noted above, the payment for all internal costs associated with transition services is presented on a gross basis as service revenue.

XML

Property and Equipment, Net (Narrative) (Detail) (USD $) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Property, Plant and Equipment [Line Items]
Depreciation and amortization expense	$ 2.8	$ 3.0	$ 3.2

XML

Leases, Licensed Technology and Other Commitments (Detail) (USD $)	12 Months Ended
	Dec. 31, 2011 Employee sqft	Dec. 31, 2010	Dec. 31, 2009
Lease Commitments and Contingencies [Line Items]
Square footage of office and laboratory facility acquired through non-cancelable operating lease	100,000
Operating lease expiration date	July 2019
Operating lease, number of renewal options	2
Operating lease, renewal options in years	5 years
Operating lease, letters of credit outstanding	$ 699,000
Operating lease rent expense, sublease income	67,000	28,000
Operating lease rent expense net of sublease income	2,000,000	2,100,000	2,100,000
Operating lease, future lease payments due current	3,300,000
Operating lease, future lease payments due in two years	5,200,000
Operating lease, future lease payments due in three years	5,300,000
Operating lease, future lease payments due in four years	5,400,000
Operating lease, future lease payments due in five years	5,500,000
Operating lease, future lease payments due after five years	14,500,000
Operating lease, future sublease rental income in one year	39,000
License fees paid	145,000	145,000	145,000
Future expected annual license fees	145,000
Number of officers under employment agreements	8
Number of years officers are under employment agreements	2 years
Aggregate base salaries payable to officers, due next year	3,000,000
Aggregate base salaries payable to officers, due in two years	$ 1,500,000

XML

Calculation of Net Income (Loss) and the Number of Shares Used to Compute Basic and Diluted Earnings per Share (Detail) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]
Net income (loss)	$ (123,603)	$ 85,248	$ (80,008)
Weighted average shares outstanding - basic	132,375	113,020	93,330
Dilutive stock options		572
Restricted stock and restricted stock units		1,142
Weighted average shares outstanding -- diluted	132,375	114,734	93,330

XML

CONSOLIDATED BALANCE SHEETS (USD $) In Thousands, unless otherwise specified	Dec. 31, 2011	Dec. 31, 2010
Current assets:
Cash and cash equivalents	$ 306,256	$ 103,630
Amounts due under license agreements (Note 2)	34	407
Other current assets	1,277	1,135
Total current assets	307,567	105,172
Restricted cash	749	749
Property and equipment, net (Note 3)	6,611	7,037
Intangible and other assets, net (Note 4)	5,785	7,072
Total assets	320,712	120,030
Current liabilities:
Accounts payable	5,728	3,122
Current portion of long-term debt and capital lease obligations (Note 5)	1,454	1,466
Accrued compensation and benefits	1,209	1,127
Accrued product development expenses	11,948	8,189
Other accrued expenses	3,634	1,664
Current portion of deferred executive compensation (Note 6)	1,032	693
Current portion of deferred revenue	231
Other current liabilities	136	136
Total current liabilities	25,372	16,397
Long-term debt and capital lease obligations (Note 5)	11,215	8,294
Other long-term liabilities	1,854	330
Deferred revenue	768
Deferred executive compensation (Note 6)	2,723	2,118
Warrant liability (Notes 8 and 9)	58,639	28,815
Commitments (Note 7)
Stockholders' equity (Notes 8, 10 and 11):
Preferred stock, $.01 par value, authorized 10,000,000 shares, none issued and outstanding
Common stock, $.001 par value, authorized 240,000,000 shares in 2011 and 2010; shares issued and outstanding 157,608,702 shares in 2011, 126,942,431 shares in 2010	158	127
Additional paid-in capital	776,946	497,309
Accumulated deficit	(556,963)	(433,360)
Total stockholders' equity	220,141	64,076
Total liabilities and stockholders' equity	$ 320,712	$ 120,030

XML

Stock Plans-Narrative (Detail)	1 Months Ended	12 Months Ended
	Jun. 30, 2008	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 1997
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, vesting period		4 years
Stock options, expiration period		10 years
Stock Plan 2006 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for awards under the plan		2,818,832
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Reserved common stock for issuance under the plan					500,000
Additional shares of common stock reserved	500,000
Shares of common stock issued under the plan		87,331	176,318	401,797
Employee Stock Purchase Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Purchase price of common stock by employees	85.00%

XML

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Cash flows from operating activities:
Net income (loss)	$ (123,603)	$ 85,248	$ (80,008)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation, amortization and impairments	4,614	6,147	4,219
Accretion of discount on marketable securities			(20)
Stock-based compensation	7,675	4,836	4,355
Deferred executive compensation expense	1,719	1,477	1,134
Revaluation of warrant liability	46,715	19,532	7,804
Increase (decrease) from:
Other current and non-current assets	(145)	814	2,092
Amounts due under license and collaboration agreements	373	3,176	1,997
Accounts payable	2,394	(1,684)	(4,564)
Accrued compensation and benefits	82	76	233
Accrued product development expenses	3,759	117	(1,864)
Other accrued expenses	1,271	(1,043)	(1,282)
Other liabilities	1,660	18	662
Deferred revenue	999	(111,611)	14,347
Deferred executive compensation paid	(775)	(685)	(1,009)
Net cash provided by (used in) operating activities	(53,262)	6,418	(51,904)
Cash flows from investing activities:
Acquisitions of marketable securities			(7,599)
Proceeds from maturities of marketable securities			22,426
Change in restricted cash			(50)
Investment in property and equipment	(1,452)	(1,344)	(2,198)
Investment in intangible assets	(671)	(691)	(1,308)
Net cash provided by (used in) investing activities	(2,123)	(2,035)	11,271
Cash flows from financing activities:
Proceeds from long-term borrowings	4,375
Repayment of long-term borrowings	(1,400)	(1,925)	(1,400)
Proceeds from issuance of common stock, net of issuance costs	243,058	57,515	58,370
Proceeds from issuance of common stock pursuant to warrants	8,080	2,624
Principal payments under capital lease obligations	(66)	(118)	(87)
Payment of tax withholding obligations related to stock compensation	(827)
Proceeds from issuance of common stock pursuant to stock option and purchase plans	4,791	789	568
Net cash provided by financing activities	258,011	58,885	57,451
Net increase in cash and cash equivalents	202,626	63,268	16,818
Cash and cash equivalents, beginning of year	103,630	40,362	23,544
Cash and cash equivalents, end of year	306,256	103,630	40,362
Supplemental disclosures:
Interest paid	230	182	302
Property and equipment acquired through capital lease		19	206
Non-cash transaction - property and equipment included in accounts payable or accruals	$ 911

XML

Related Party Transaction - Narrative (Detail) (USD $) In Thousands, except Share data, unless otherwise specified	1 Months Ended				12 Months Ended
	Dec. 31, 2011	Oct. 31, 2010	Aug. 31, 2009	Feb. 28, 2009	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Related Party Transaction [Line Items]
Shares of common stock offered for sale	24,725,000	16,000,000	21,850,000	14,378,698
Issuance of common stock	$ 243,058	$ 57,515	$ 35,600	$ 22,800	$ 243,058	$ 57,515	$ 58,370
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Shares of common stock offered for sale			1,714,286
Offering price of common stock			$ 1.75
Issuance of common stock			$ 3,000

XML

Intangible and Other Assets, Net (Narrative) (Detail) (USD $)	12 Months Ended
	Dec. 31, 2011 Year	Dec. 31, 2010 Year	Dec. 31, 2009 Year
Finite-Lived Intangible Assets [Line Items]
Finite lived intangible assets, amortization expense	$ 1,700,000	$ 900,000	$ 1,000,000
Finite lived intangible assets, Weighted average amortization period	14.9	14.8	15.2
Finite lived intangible assets, estimated future amortization expense year one	470,000
Finite lived intangible assets, estimated future amortization expense year two	435,000
Finite lived intangible assets, estimated future amortization expense year three	435,000
Finite lived intangible assets, estimated future amortization expense year four	435,000
Finite lived intangible assets, estimated future amortization expense year five	435,000
Finite lived intangible assets, estimated future amortization expense after year five	3,500,000
Capitalized patent and license costs [Member]
Finite-Lived Intangible Assets [Line Items]
Research and development expense	$ 312,000	$ 2,400,000	$ 47,000

XML

Property and Equipment, Net (Tables)

12 Months Ended

Dec. 31, 2011

Schedule of Property and Equipment, Net

Property and equipment, net, was comprised of the following at December 31:

In thousands	2011			2010
Leasehold improvements	$	22,252		$	22,090
Construction in progress		699			---
Equipment and furniture		17,032			15,675
		39,983			37,765
Less accumulated depreciation and amortization		(33,372	)		(30,728	)
	$	6,611		$	7,037

Schedule of Assets Under Capital Leases

The Company leases certain assets under capital leases having terms up to three years.  Assets under capital leases included in property and equipment were as follows at December 31:

In thousands	2011			2010
Equipment and furniture	$	392		$	420
Less accumulated depreciation and amortization		(257	)		(172	)
	$	135		$	248

XML

Schedule of Long-term Debt and Capital Lease Obligations (Detail) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2011	Dec. 31, 2010
Debt Instrument [Line Items]
Bank term loan	$ 12,600	$ 9,625
Capital lease obligations	69	135
Debt and capital lease obligation	12,669	9,760
Less current portion	(1,454)	(1,466)
Long-term debt and capital lease obligations	$ 11,215	$ 8,294

XML

Long-term Debt and Capital Lease Obligations (Tables)

12 Months Ended

Dec. 31, 2011

Schedule of Long-term Debt and Capital Lease Obligations

Long-term debt and capital lease obligations were comprised of the following at December 31:

In thousands	2011			2010
Bank term loan	$	12,600		$	9,625
Capital lease obligations		69			135
		12,669			9,760
Less current portion		(1,454	)		(1,466	)
	$	11,215		$	8,294

Future Scheduled Principal Payments Due Under Financing Obligations

The future scheduled principal payments due under these financing obligations were as follows at December 31, 2011:

In thousands	Bank Term Loan			Capital Lease Obligations
Year ended December 31:
2012	$	1,400		$	54
2013		2,100			15
2014		4,200			---
2015		4,900			---
		12,600			69
Less current portion		(1,400	)		(54	)
Long-term portion	$	11,200		$	15

XML

Nature of Business and Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2011

Nature of Business and Summary of Significant Accounting Policies

1.     Nature of Business and Summary of Significant Accounting Policies

Nature of Business

ARIAD’s vision is to transform the lives of cancer patients with breakthrough medicines.  The Company’s mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need – aggressive cancers where current therapies are inadequate.  The Company’s goal is to build a fully integrated oncology company.

The Company currently has three product candidates in development.  Ponatinib is being studied in Phase 1 and Phase 2 clinical trials in patients with hematologic cancers, including chronic myeloid leukemia and Philadelphia positive acute lymphoblastic leukemia.  AP26113 is being studied in a Phase 1/2 clinical trial in patients with advanced solid tumors including non-small cell lung cancer.  Ridaforolimus is being studied in multiple clinical trials in patients with various types of cancers.  Under the terms of a license agreement described in Note 2, Merck, Sharpe & Dohme Corp. (“Merck”) is responsible for all activities related to the development, manufacture, and commercialization of ridaforolimus.  In addition to our lead development programs, the Company has a focused drug discovery program centered on small-molecule therapies that are molecularly targeted to cell-signaling pathways implicated in cancer.

Principles of Consolidation

The consolidated financial statements include the accounts of ARIAD Pharmaceuticals, Inc. and its wholly-owned subsidiaries, ARIAD Corporation, ARIAD Pharma S.A. and ARIAD Pharma Ltd.  Intercompany accounts and transactions have been eliminated in consolidation.  Following the close of business on December 31, 2011, our wholly-owned subsidiary ARIAD Corporation was merged with and into ARIAD Pharmaceuticals, Inc.

Accounting Estimates

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts and disclosure of assets and liabilities at the date of the consolidated financial statements and the reported amounts and disclosure of revenue and expenses during the reporting period.  Actual results could differ from those estimates.

Cash Equivalents

Cash equivalents include short-term, highly liquid investments, which consist principally of United States government and agency securities, purchased with remaining maturities of 90 days or less, and money market accounts.

Restricted Cash

Restricted cash consists of cash balances held as collateral for outstanding letters of credit related to the lease of the Company’s laboratory and office facility and other purposes.

Property and Equipment

Property and equipment are recorded at cost.  Depreciation is recorded using the straight-line method over the estimated useful lives of the assets (3 to 10 years).  Leasehold improvements and assets under capital leases are amortized over the shorter of their useful lives or lease term using the straight-line method.

Intangible and Other Assets

Intangible and other assets consist primarily of purchased technology and capitalized patent and license costs.  The cost of purchased technology, patents and patent applications, costs incurred in filing patents and certain license fees are capitalized.  Capitalized costs related to purchased technology are amortized over the estimated useful life of the technology.  Capitalized costs related to issued patents are amortized over a period not to exceed seventeen years or the remaining life of the patent, whichever is shorter, using the straight-line method.  Capitalized license fees are amortized over the periods to which they relate.  In addition, capitalized costs are expensed when it becomes determinable that the related patents, patent applications or technology will not be pursued.

Impairment of Long-Lived Assets

The Company reviews its long-lived assets, including the above-mentioned intangible assets, for impairment when events or changes in circumstances indicate that the carrying amount of a long-lived asset may not be recoverable.  Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset.  If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets.

Accrued Rent

The Company recognizes rent expense for leases with increasing annual rents on a straight-line basis over the term of the lease.  The amount of rent expense in excess of cash payments is classified as accrued rent.  Any lease incentives received are deferred and amortized over the term of the lease.  At December 31, 2011, other liabilities on the balance sheet include accrued rent of $1.7 million.

Revenue Recognition

The Company generates revenue from license and collaboration agreements with third parties related to use of the Company’s technology and/or development and commercialization of product candidates.  Such agreements may provide for payment to the Company of up-front payments, periodic license payments, milestone payments and royalties.

Revenue is recognized when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed and determinable and collection is reasonably assured.  Revenue arrangements with multiple elements are divided into separate units of accounting if certain criteria are met, including whether the delivered element has stand-alone value to the customer.  When deliverables are separable, consideration received is allocated to the separate units of accounting based on the relative selling price of each deliverable and the appropriate revenue recognition principles are applied to each unit.

The Company also generates service revenue from license agreements with third parties related to internal services provided under such agreements.  Service revenue is recognized as the services are delivered.

Income Taxes

The Company accounts for income taxes using an asset and liability approach to financial accounting and reporting for income taxes.  Deferred income tax assets and liabilities are computed annually for differences between the financial statement basis and the income tax basis of assets and liabilities that will result in taxable or deductible amounts in the future.  Such deferred income tax computations are based on enacted tax laws and rates applicable to the years in which the differences are expected to affect taxable income.  A valuation allowance is established when it is necessary to reduce deferred income tax assets to the amount that is considered to be more-likely-than-not realizable.

The Company does not recognize a tax benefit unless it is more likely than not that the tax position will be sustained upon examination, including resolution of any related appeals or litigation processes, based on the technical merits of the position.  The tax benefit that is recorded for these positions is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement.

Segment Reporting

The Company organizes itself into one operating segment reporting to the chief executive officer.

Stock-Based Compensation

The Company awards stock options and other equity-based instruments to its employees, directors and consultants and provides employees the right to purchase common stock (collectively “share-based payments”), pursuant to stockholder approved plans.  Compensation cost related to such awards is measured based on the fair value of the instrument on the grant date and is recognized on a straight-line basis over the requisite service period, which generally equals the vesting period.

Executive Compensation Plan

The Company has an unfunded deferred executive compensation plan that defers the payment of annual bonus awards to officers to future periods as specified in each award.  The value of the awards is indexed to the value of specified mutual funds.  The Company accrues a liability based on the value of the awards ratably over the vesting period (generally four years).  The recorded balances of such awards are increased or decreased based on the actual total return and quoted market prices of the specified mutual funds.

Subsequent Events

The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure.

Recent Accounting Pronouncements

In April 2010, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2010-17, Revenue Recognition - Milestone Method, which provides guidance on determining whether a milestone is substantive including the criteria that must be met for a milestone to be considered a substantive milestone and the recognition of consideration received upon achievement of a substantive milestone.  ASU No. 2010-17 is effective for fiscal years, and interim periods within those fiscal years, beginning on or after June 15, 2010.  The Company adopted this ASU on January 1, 2011 with no material impact on its financial statements.

In October 2009, the FASB issued authoritative guidance that modifies the accounting for multiple element revenue arrangements.  This guidance requires an entity to allocate revenue to each unit of accounting in multiple deliverable arrangements based on the relative selling price of each deliverable.  It also changes the level of evidence of stand-alone selling prices required to separate deliverables by requiring an entity to make its best estimate of the stand-alone selling price of the deliverables when more objective evidence of selling price is not available.  This guidance is effective for fiscal years beginning after June 15, 2010 and may be applied prospectively to new or materially modified arrangements after the effective date or retrospectively.  The Company adopted this guidance on January 1, 2011 and although the adoption did not materially impact its financial condition, results of operations, or cash flows, this guidance may impact the Company’s determination of the separation of deliverables for future arrangements.

In June 2011, the FASB issued ASU No. 2011-05, Presentation of Comprehensive Income, which requires the presentation of other comprehensive income in either a continuous statement of comprehensive income or in two separate but consecutive statements.  ASU No. 2011-05 is effective for fiscal years, and interim periods within those fiscal years, beginning on or after December 15, 2011 and requires retrospective application.  This guidance will require a change in the presentation of the financial statements, however it will not have a material impact unless the Company has components of other comprehensive income other than net income (loss).

XML

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2011	Dec. 31, 2010
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, authorized	10,000,000	10,000,000
Preferred stock, issued
Preferred stock, outstanding
Common stock, par value	$ 0.001	$ 0.001
Common stock, authorized	240,000,000	240,000,000
Common stock, shares issued	157,608,702	126,942,431
Common stock, shares outstanding	157,608,702	126,942,431

XML

Stock-Based Compensation

12 Months Ended

Dec. 31, 2011

Stock-Based Compensation

11.   Stock-Based Compensation

The Company awards stock options and other equity-based instruments to its employees, directors and consultants and provides employees the right to purchase common stock (collectively “share-based payments”), pursuant to stockholder approved plans.  The Company’s statement of operations included total compensation cost from share-based payments for the years ended December 31, as follows:

In thousands	2011		2010		2009
Compensation cost from:
Stock options	$	2,893	$	1,879	$	3,068
Stock and stock units		4,601		2,834		1,096
Purchases of common stock at a discount		181		123		191
	$	7,675	$	4,836	$	4,355
Compensation cost included in:
Research and development expenses	$	3,782	$	2,444	$	2,123
General and administrative expenses		3,893		2,392		2,232
	$	7,675	$	4,836	$	4,355

Stock Options

Stock options are granted with an exercise price equal to the closing market price of the Company’s common stock on the date of grant.  Stock options generally vest ratably over four years and have contractual terms of ten years.  Stock options are valued using the Black-Scholes option valuation model and compensation cost is recognized based on such fair value over the period of vesting on a straight-line basis.

The following table summarizes information about stock options as of and for the years ended December 31, 2011, 2010 and 2009:

In thousands, except per share amounts	2011		2010		2009
Weighted average fair value of options granted, per share	$	5.80	$	2.43	$	1.03
Total cash received from exercises of stock options		4,648		418		206
Total intrinsic value of stock options exercised		5,169		331		271

The weighted average fair value of options granted in the years ended December 31, 2011, 2010 and 2009, reflect the following weighted-average assumptions:

	2011		2010		2009
Expected life of options granted (in years)	7.48		6.75		7.04
Expected volatility	74.77	%	78.54	%	70.68	%
Risk-free rate	2.53	%	2.57	%	2.75	%
Expected dividends	0	%	0	%	0	%

The expected life assumption is based on an analysis of historical behavior of participants related to options awarded over time.  The expected volatility assumption for the years ended December 31, 2011, 2010 and 2009 is based on the implied volatility of the Company’s common stock, derived from analysis of historical traded and quoted options on the Company’s common stock over the period commensurate with the expected life of the options granted.  The risk-free rate is based on the forward U.S. Treasury yield curve.  The expected dividends reflect the Company’s current and expected future policy for dividends on its common stock.

Stock option activity under the Company’s stock plans for the year ended December 31, 2011 was as follows:

	Number of Shares		Weighted Average Exercise Price Per Share
Options outstanding, January 1, 2011		7,177,191	$	4.42
Granted		1,599,519	$	8.05
Forfeited		225,295	$	4.16
Exercised		1,170,086	$	4.40
Options outstanding, December 31, 2011		7,381,329	$	5.22

The following table summarizes information about stock options outstanding as of December 31, 2011:

	Options Outstanding		Options Exercisable		Options Vested and Expected To Vest
Number of options		7,381,329		5,055,872		7,066,555
Weighted average exercise price per share	$	5.22	$	4.84	$	5.21
Aggregate intrinsic value (in 000’s)	$	51,878	$	37,468	$	49,717
Weighted average remaining contractual term	5.52 years		4.07 years		5.38 years

Options expected to vest consist of options scheduled to vest in the future less expected forfeitures.

At December 31, 2011, total unrecognized compensation cost related to non-vested stock options outstanding amounted to $7.1 million.  That cost is expected to be recognized over a weighted-average period of 2.85 years.

Stock and Stock Unit Grants

Stock and stock unit grants are provided to non-employee directors as compensation and generally carry no restrictions as to resale or are fully vested upon grant.  Stock and stock unit grants to officers carry restrictions as to resale for periods of time or vesting provisions over time as specified in the grant.  Stock and stock unit grants are valued at the closing market price of the Company’s common stock on the date of grant and compensation expense is recognized over the requisite service period, vesting period or period during which restrictions remain on the common stock or stock units granted.

Stock and stock unit activity under the Company’s stock plans for the year ended December 31, 2011 was as follows:

	Number of Shares		Weighted Average Grant Date Fair Value
Outstanding, January 1, 2011		2,779,300	$	2.83
Granted		1,255,681	$	7.43
Forfeited		115,632	$	4.05
Vested or restrictions lapsed		1,134,323	$	3.69
Outstanding, December 31, 2011		2,785,026	$	4.51

Included in stock and stock units granted in the above table are 392,500 performance share units that will vest upon regulatory approval of ponatinib by the U.S. Food and Drug Administration on or before December 31, 2016.  Compensation expense related to these performance share units will be recognized upon achieving such regulatory approval.

At December 31, 2011, total unrecognized compensation cost related to time-vested stock and stock unit awards amounted to $5.5 million.  That cost is expected to be recognized over a weighted average of 1.82 years.  Unrecognized compensation cost related to stock units with performance-based vesting conditions was $3.1 million at December 31, 2011.  Compensation expense for these awards will begin to be recognized when vesting is probable.  The total fair value of stock and stock unit awards that vested in 2011, 2010 and 2009 was $8.0 million, $1.6 million and $279,000, respectively.

Purchase of Common Stock Pursuant to Employee Stock Purchase Plan

Purchases of common stock by employees are provided pursuant to the Company’s employee stock purchase plan.  Purchase price is calculated as 85 percent of the lower of the closing price of our common stock on the first trading day or last trading day of each calendar quarter.  Compensation cost is equal to the fair value of the discount on the date of grant and is recognized as compensation in the period of purchase.

XML

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2011	Feb. 15, 2012	Jun. 30, 2011
Document Type	10-K
Amendment Flag	true
AmendmentDescription	The sole purpose of this Amendment No. 1 to the Annual Report on Form 10-K of ARIAD Pharmaceuticals, Inc. (the “Company”) for the fiscal year ended December 31, 2011, filed with the Securities and Exchange Commission on February 29, 2012 (the “Form 10-K”), is to furnish the Interactive Data Files on Exhibit 101. As permitted by Rule 405(a)(2)(ii) of Regulation S-T, the Company is furnishing the Interactive Data Files on Exhibit 101 by amendment within 30 days of the original filing date of the Form 10-K. No other changes have been made to the Form 10-K, and this Amendment has not been updated to reflect events occurring subsequent to the filing of the Form 10-K. Pursuant to Rule 406T of Regulation S-T, the Interactive Data Files on Exhibit 101 are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and are otherwise not subject to liability under those sections.
Document Period End Date	Dec. 31, 2011
Document Fiscal Year Focus	2011
Document Fiscal Period Focus	FY
Trading Symbol	ARIA
Entity Registrant Name	ARIAD PHARMACEUTICALS INC
Entity Central Index Key	0000884731
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		158,929,544
Entity Public Float			$ 1,220,167,480

XML

Net Income (Loss) Per Share

12 Months Ended

Dec. 31, 2011

Net Income (Loss) Per Share

12.   Net Income (Loss) Per Share

Basic net income (loss) per share amounts have been computed based on the weighted-average number of common shares outstanding.  Diluted net income (loss) per share amounts have been computed based on the weighted-average number of common shares outstanding plus the dilutive effect of potential common shares.  The computation of potential common shares has been performed using the treasury stock method.  The changes in income or loss that would result if the warrants were reported as an equity instrument are reflected as an adjustment to the numerator when warrants would be dilutive.  The warrants are antidilutive for all periods presented.  When net loss is reported, diluted and basic net loss per share amounts are the same as the impact of potential common shares is antidilutive.

The calculation of net income (loss) and the number of shares used to compute basic and diluted earnings per share for the years ended December 31, 2011, 2010 and 2009 are as follows:

In thousands	2011			2010		2009
Net income (loss)	$	(123,603	)	$	85,248	$	(80,008	)
Weighted average shares outstanding - basic		132,375			113,020		93,330
Dilutive stock options		---			572		---
Restricted stock and restricted stock units		---			1,142		---
Weighted average shares outstanding ­- diluted		132,375			114,734		93,330

For the years ended December 31, 2011, 2010 and 2009, the following potentially dilutive securities were not included in the computation of net income (loss) per share because the effect would be anti-dilutive:

In thousands	2011		2010		2009
Stock options		7,381		5,852		7,684
Restricted stock and restricted stock units		2,785		---		1,489
Warrants		5,806		9,564		10,784
		15,972		15,416		19,957

XML

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) In Thousands, except Per Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
License and collaboration revenue (Note 2)	$ 25,189	$ 174,460	$ 8,302
Service revenue	111	4,520
Total revenue	25,300	178,980	8,302
Operating expenses:
Research and development	77,743	57,985	63,447
General and administrative	24,380	16,095	16,888
Total operating expenses	102,123	74,080	80,335
Income (loss) from operations	(76,823)	104,900	(72,033)
Other income (expense):
Interest income	167	86	116
Interest expense	(232)	(206)	(287)
Revaluation of warrant liability	(46,715)	(19,532)	(7,804)
Other income (expense), net	(46,780)	(19,652)	(7,975)
Net income (loss)	$ (123,603)	$ 85,248	$ (80,008)
Net income (loss) per share - basic	$ (0.93)	$ 0.75	$ (0.86)
- diluted	$ (0.93)	$ 0.74	$ (0.86)
Weighted-average number of shares of common stock outstanding - basic	132,375	113,020	93,330
- diluted	132,375	114,734	93,330

XML

Executive Compensation Plan

12 Months Ended

Dec. 31, 2011

Executive Compensation Plan

6.     Executive Compensation Plan

Under the Company’s deferred executive compensation plan, the Company accrues a liability for the value of the awards ratably over the vesting period.  The grant date value of awards made in 2011, 2010 and 2009 were $1.6 million, $1.8 million and $1.1 million, respectively.  The net expense for this plan was $1.7 million, $1.5 million and $1.1 million in 2011, 2010 and 2009, respectively.  The estimated future expense for unvested awards based on the value at December 31, 2011, is $1.5 million, $544,000 and $136,000, for 2012, 2013 and 2014, respectively.

XML

Long-term Debt and Capital Lease Obligations

12 Months Ended

Dec. 31, 2011

Long-term Debt and Capital Lease Obligations

5.     Long-term Debt and Capital Lease Obligations

Long-term debt and capital lease obligations were comprised of the following at December 31:

In thousands	2011			2010
Bank term loan	$	12,600		$	9,625
Capital lease obligations		69			135
		12,669			9,760
Less current portion		(1,454	)		(1,466	)
	$	11,215		$	8,294

In January 2011, the Company amended the existing term loan with the bank.  The amendment increased the outstanding balance of the loan from $9.6 million at December 31, 2010 to $14.0 million, extended the maturity date from March 31, 2013 to December 31, 2015, and re-set the quarterly repayment provisions with payments increasing from 2.5 percent of the principal amount in the first quarter, commencing on March 31, 2011, to 8.75 percent of the principal amount in the final quarter, together with interest throughout the term of the loan.

The loan bears interest at LIBOR plus 1.25 to 2.25 percent, depending on the percentage of the Company’s liquid assets on deposit with or invested through the bank, or at the prime rate.  The effective interest rate on the loan was 1.79 percent at December 31, 2011.  The loan is secured by a lien on all assets of the Company excluding intellectual property, which the Company has agreed not to pledge to any other party.  The loan requires the Company to maintain a minimum of $15.0 million in unrestricted cash, cash equivalents and investments.  The loan also contains certain covenants that restrict additional indebtedness, additional liens and sales of assets, and dividends, distributions or repurchases of common stock.

In addition, the Company leases certain equipment under capital leases with original terms of generally three years.  These leases have effective interest rates ranging from 5.6 percent to 7.2 percent and are secured by the underlying leased assets.

The future scheduled principal payments due under these financing obligations were as follows at December 31, 2011:

In thousands	Bank Term Loan			Capital Lease Obligations
Year ended December 31:
2012	$	1,400		$	54
2013		2,100			15
2014		4,200			---
2015		4,900			---
		12,600			69
Less current portion		(1,400	)		(54	)
Long-term portion	$	11,200		$	15

XML

Intangible and Other Assets, Net (Tables)

12 Months Ended

Dec. 31, 2011

Schedule of Intangible and Other Assets, Net

Intangible and other assets, net, were comprised of the following at December 31:

In thousands	2011			2010
Capitalized patent and license costs	$	6,799		$	6,465
Purchased technology		5,901			5,901
		12,700			12,366
Less accumulated amortization		(6,957	)		(5,332	)
		5,743			7,034
Other assets		42			38
	$	5,785		$	7,072

XML

Income Taxes

12 Months Ended

Dec. 31, 2011

Income Taxes

13.   Income Taxes

The Company is subject to U.S. federal and Massachusetts state corporate income taxes.  For the years ended December 31, 2011, 2010 and 2009, the Company did not have any federal or state income tax expense given its continued cumulative net operating losses.  A reconciliation of the federal statutory corporate income tax rate to the effective income tax rate for the years ended December 31, 2011, 2010 and 2009 is as follows:

	2011		2010		2009
Statutory federal income tax rate	(35	)%	35	%	(35	)%
State income tax rate, net of federal benefit	(4	)	5		(6	)
Revaluation of warrant liability	13		8		3
Other permanent differences	---		1		1
Change in valuation allowance	26		(49	)	37
Effective tax rate	0	%	0	%	0	%

The components of deferred income taxes were as follows at December 31:

In thousands	2011			2010
Deferred tax liabilities:
Intangibles	$	2,385		$	2,813
Deferred tax assets:
Net operating loss carryforwards		161,951			134,065
Federal and state tax credit carryovers		23,380			24,489
Depreciation		4,924			4,837
Stock-based compensation		3,420			3,122
Other		2,158			1,289
Total deferred tax assets		195,833			167,802
Deferred tax assets, net		193,448			164,989
Valuation allowance		(193,448	)		(164,989	)
Total deferred taxes	$	---		$	---

At December 31, 2011, the Company had available estimated net operating loss carryforwards and research and development credit carryforwards for federal and state tax reporting purposes as follows:

	Amount		Expiring if not utilized
	(in 000s)
Net operating loss carryforwards:
Federal	$	457,459	2012 through 2031
State	$	79,197	2012 through 2016
Research and development credit carryforwards:
Federal	$	18,448	2012 through 2031
State	$	7,588	2012 through 2026

Since the Company has not yet achieved sustained profitable operations, management believes the deferred tax assets do not satisfy the more-likely-than-not realization criteria and has recorded a valuation allowance for the entire net deferred tax assets.  The valuation allowance increased by $28.5 million and $21.9 million in 2011 and 2009, respectively, due to taxable losses and resulting increases in net operating loss carryforwards.  The valuation allowance decreased by $43.5 million in 2010 due to the recognition of previously deferred revenue for tax purposes and utilization of net operating loss carryforwards.  In 2010, the Company recognized a tax benefit from the utilization of net operating loss carryforwards for federal and state purposes of $7.9 million and $1.4 million, respectively.  The Company does not have any material uncertain tax positions.

Due to the Company’s historical net operating loss position, the Company’s U.S. federal and Massachusetts tax returns remain open to examination for three years after the Company utilizes that year’s net operating loss carryforward.  The Company’s earliest year which generated a net operating loss including in the Company’s current net operating loss carryforward is 1997 for U.S. federal tax purposes and 2006 for Massachusetts state tax purposes.

XML

Fair Value of Financial Instruments

12 Months Ended

Dec. 31, 2011

Fair Value of Financial Instruments

9.     Fair Value of Financial Instruments

The Company provides disclosure of financial assets and financial liabilities that are carried at fair value based on the price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.  Fair value measurements may be classified based on the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities using the following three levels:

Level 1—Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.

Level 2—Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.) and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).

Level 3—Unobservable inputs that reflect the Company's estimates of the assumptions that market participants would use in pricing the asset or liability.  The Company develops these inputs based on the best information available, including its own data.

The following table presents information about the Company’s assets and liabilities as of December 31, 2011 and 2010 that are measured at fair value on a recurring basis and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value:

	December 31, 2011
In thousands	Total		Level 1		Level 2		Level 3
Warrant liability	$	58,639	$	---	$	58,639	$	---

	December 31, 2010
In thousands	Total		Level 1		Level 2		Level 3
Warrant liability	$	28,815	$	---	$	---	$	28,815

The Company’s warrant liability is carried at fair value and, at December 31, 2010, was classified as Level 3 in the fair value hierarchy due to the use of significant unobservable inputs.  At December 31, 2011, the unobservable inputs did not have a significant impact on the valuation of the warrant liability and, therefore, the Company classified the warrant liability as Level 2 within the fair value hierarchy.  This reclassification from Level 3 reflects that the warrants’ exercise price is significantly lower than the market price of the underlying common stock on the reporting date.  The fair value of the warrants is determined using the Black-Scholes option valuation model, applying the following inputs as of December 31, 2011, 2010 and 2009:

	2011			2010			2009
Market price per share of the Company’s common stock	$	12.25		$	5.10		$	2.28
Risk-free interest rate		0.015	%		0.34	%		1.23	%
Expected term (years)		0.2			1.2			2.2
Dividend yield		---			---			---
Volatility		59.9	%		54.0	%		79.0	%

The increase in the fair value of the warrants was recognized in other income (expense) in the consolidated statement of operations.  The changes in the fair value of the warrant liability for the years ended December 31, 2011, 2010 and 2009 were as follows:

In thousands	2011			2010			2009
Balance, beginning of year	$	28,815		$	11,363		$	---
Issuance of warrants		---			---			3,559
Revaluation of warrants		46,715			19,532			7,804
Exercise of warrants		(16,891	)		(2,080	)		---
Balance, end of year	$	58,639		$	28,815		$	11,363

The carrying amounts of cash equivalents, accounts payable and accrued liabilities approximate fair value because of their short-term nature.  The carrying amount of the Company’s bank term loan approximates fair value due to its variable interest rate and other terms.  The Company’s obligation under its executive compensation plan is based in part on the current fair market value of specified mutual funds, which is therefore stated at its estimated fair value.

XML

Leases, Licensed Technology and Other Commitments

12 Months Ended

Dec. 31, 2011

Leases, Licensed Technology and Other Commitments

7.     Leases, Licensed Technology and Other Commitments

Facility Lease

The Company conducts its operations in a 100,000 square foot office and laboratory facility under a non-cancelable operating lease.  The lease was amended in 2011 and provides that the current lease term extends to July 2019 with two consecutive five-year renewal options.  The Company maintains an outstanding letter of credit of $699,000 in accordance with the terms of the amended lease.  Rent expense, net of sublease income of $67,000 in 2011 and $28,000 in 2010, amounted to $2.0 million, $2.1 million and $2.1 million in 2011, 2010 and 2009, respectively.  Future minimum annual rental payments through July 2019 are $3.3 million in 2012, $5.2 million in 2013, $5.3 million in 2014, $5.4 million in 2015, $5.5 million in 2016, and $14.5 million thereafter, which are net of expected sub-lease income of $39,000 in 2012.

Licensed Technology

The Company has entered into agreements with several universities under the terms of which the Company has received exclusive licenses to technology and intellectual property.  The agreements, which are generally cancelable by the Company, provide for the payment of license fees and/or minimum payments, which are generally creditable against future royalties.  Fees paid by the Company amounted to $145,000 in each of 2011, 2010 and 2009, and are expected to amount to $145,000 in 2012 and thereafter.  In addition, the agreements provide for payments upon the achievement of certain milestones in product development.  The agreements also require the Company to fund certain costs associated with the filing and prosecution of patent applications.

Other Commitments

The Company has entered into various employment agreements with officers of the Company.  The agreements for eight of these officers have remaining terms as of December 31, 2011 of up to two years, providing for aggregate base salaries of $3.0 million for 2012 and $1.5 million for 2013.

XML

Stockholders' Equity and Warrants

12 Months Ended

Dec. 31, 2011

Stockholders' Equity and Warrants

8.     Stockholders’ Equity and Warrants

Preferred Stock

The Company has authorized 10,000,000 shares of preferred stock which the Board of Directors is authorized to designate and issue in different series.

Common Stock and Warrants

At December 31, 2011, the Company had 240,000,000 shares of common stock authorized.

On February 25, 2009, the Company sold 14,378,698 shares of its common stock in a registered direct offering to institutional investors, at a purchase price of $1.69 per share, resulting in net proceeds after fees and expenses of $22.8 million.  The investors also received warrants to purchase an additional 10,784,024 shares of the Company’s common stock exercisable at a price of $2.15 per share in cash or pursuant to the net exercise provisions of the warrants.  At the election of the warrant holder, upon certain transactions, including a merger, tender offer or sale of all or substantially all of the assets of the Company, the holder may receive cash in exchange for the warrant, in an amount determined by application of the Black-Scholes option valuation model at the time of any such event, if the consideration received by the stockholders from such transaction is less than $2.15 per share.  The warrants became exercisable on August 25, 2009 and expired on February 25, 2012.  During the year ended December 31, 2010, 1,220,414 warrants were exercised for proceeds to the Company of $2.6 million.  During the year ended December 31, 2011, a total of 3,757,767 warrants were exercised by the holders for proceeds to the Company of approximately $8.1 million.  Prior to exercise, the warrants were recorded at fair value, with the adjustment to carrying value recognized in earnings.  Upon exercise, the sum of the fair value of the exercised warrants and the proceeds received are credited to additional paid-in-capital and totaled $25.0 million and $4.7 million in 2011 and 2010, respectively.  At December 31, 2011, there were 5,805,843 warrants outstanding, which, when exercised in 2012, resulted in proceeds to the Company of approximately $12.5 million.  Upon the exercise of these remaining warrants, the balance of the warrant liability was credited to stockholders’ equity and the liability was eliminated.

As a result of the potential cash settlement provision, the warrants do not qualify to be classified as an equity instrument but instead are classified as a derivative liability.  Accordingly, the fair value of the warrants is reflected on the consolidated balance sheet as a liability and such fair value is adjusted at each financial reporting date with the adjustment reflected in the consolidated statement of operations.  The Company classified the warrant obligation as a long-term liability as there was no indication that a merger, tender offer or similar transaction was probable.

On August 7, 2009, the Company sold 21,850,000 shares of its common stock in an underwritten public offering, including 2,850,000 shares of common stock upon exercise by the underwriters of their over-allotment option, at a purchase price of $1.75 per share.  Net proceeds of this offering, after underwriting discounts and commissions and direct expenses, were $35.6 million.

On October 29, 2010, the Company sold 16,000,000 shares of its common stock in an underwritten public offering at a purchase price of $3.70 per share.  Net proceeds of this offering, after underwriting discounts and commissions and expenses, were approximately $57.5 million.

On December 20, 2011, the Company sold 24,725,000 shares of its common stock in an underwritten public offering at a purchase price of $10.42 per share.  Net proceeds of this offering, after underwriting discounts and commissions and expenses, were approximately $243.1 million.

On January 11, 2010, the Company filed a shelf registration statement with the U.S. Securities and Exchange Commission (“SEC”) for the issuance of common stock, preferred stock, various series of debt securities and/or warrants or rights to purchase any of such securities, either individually or in units, with a total value of up to $125 million, from time to time at prices and on terms to be determined at the time of any such offering.  This filing was declared effective on January 21, 2010.  Following the October 29, 2010 stock offering, the Company has approximately $65.8 million of securities remaining available under this shelf registration statement.

On December 14, 2011, the Company filed a shelf registration statement with the SEC for the issuance of an unspecified amount of common stock, preferred stock, various series of debt securities and/or warrants to purchase any of such securities, either individually or in units, from time to time at prices and on terms to be determined at the time of any such offering.  This filing was effective upon filing and will remain in effect for up to three years from filing.

XML

Stock Plans

12 Months Ended

Dec. 31, 2011

Stock Plans

10.   Stock Plans

ARIAD Stock Option and Stock Plans

The Company’s 1991, 1994, 2001 and 2006 stock option and stock plans (the “Plans”) provide for the awarding of nonqualified and incentive stock options, stock grants and restricted stock units to officers, directors, employees and consultants of the Company.  Stock options become exercisable as specified in the related option certificate, typically over a four-year period, and expire ten years from the date of grant.  Stock grants and restricted stock units provide the recipient with ownership of common stock subject to any rights the Company may have to repurchase the shares granted or other restrictions.  The 1991 and 1994 Plans have expired according to their terms and the 2001 Plan has no shares remaining available for grant, although existing stock options granted under these Plans remain outstanding.  As of December 31, 2011, there are 2,818,832 shares available for awards under the 2006 Plan.

Employee Stock Purchase Plan

In 1997, the Company adopted the 1997 Employee Stock Purchase Plan and reserved 500,000 shares of common stock for issuance under this plan.  In June 2008, the Plan was amended to reserve an additional 500,000 shares of common stock for issuance.  Under this plan, substantially all of the Company’s employees may, through payroll withholdings, purchase shares of the Company’s common stock at a price of 85 percent of the lesser of the fair market value at the beginning or end of each three-month withholding period.  In 2011, 2010 and 2009, 87,331, ­­­­­­­176,318 and 401,797 shares of common stock were issued under the plan, respectively.

XML

Schedule Intangible and Other Assets, Net (Detail) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2011	Dec. 31, 2010
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	$ 12,700	$ 12,366
Less accumulated amortization	(6,957)	(5,332)
Intangible assets, net	5,743	7,034
Other assets	42	38
Intangible and other assets	5,785	7,072
Capitalized patent and license costs [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	6,799	6,465
Purchased Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	$ 5,901	$ 5,901

XML

Stock-Based Compensation - Narrative (Detail) (USD $)	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted	1,599,519
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation cost related to non vested stock options outstanding	$ 7,100,000
Weighted average period of compensation cost expected to be recognized	2.85
Performance - based vesting
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted	392,500
Time-Vested Stock and Stock Units Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation cost	5,500,000
Weighted average period of compensation cost expected to be recognized	1.82
Performance-Based Vesting Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation cost	3,100,000
Stock and Stock Units Grants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total fair value of stock and stock unit awards vested	$ 8,000,000	$ 1,600,000	$ 279,000
Employee Stock Purchase Plans [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Purchase price of common stock by employees	85.00%

XML

Nature of Business and Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2011

Nature of Business

Nature of Business

ARIAD’s vision is to transform the lives of cancer patients with breakthrough medicines.  The Company’s mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need – aggressive cancers where current therapies are inadequate.  The Company’s goal is to build a fully integrated oncology company.

The Company currently has three product candidates in development.  Ponatinib is being studied in Phase 1 and Phase 2 clinical trials in patients with hematologic cancers, including chronic myeloid leukemia and Philadelphia positive acute lymphoblastic leukemia.  AP26113 is being studied in a Phase 1/2 clinical trial in patients with advanced solid tumors including non-small cell lung cancer.  Ridaforolimus is being studied in multiple clinical trials in patients with various types of cancers.  Under the terms of a license agreement described in Note 2, Merck, Sharpe & Dohme Corp. (“Merck”) is responsible for all activities related to the development, manufacture, and commercialization of ridaforolimus.  In addition to our lead development programs, the Company has a focused drug discovery program centered on small-molecule therapies that are molecularly targeted to cell-signaling pathways implicated in cancer.

Principles of Consolidation

Principles of Consolidation

The consolidated financial statements include the accounts of ARIAD Pharmaceuticals, Inc. and its wholly-owned subsidiaries, ARIAD Corporation, ARIAD Pharma S.A. and ARIAD Pharma Ltd.  Intercompany accounts and transactions have been eliminated in consolidation.  Following the close of business on December 31, 2011, our wholly-owned subsidiary ARIAD Corporation was merged with and into ARIAD Pharmaceuticals, Inc.

Accounting Estimates

Accounting Estimates

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts and disclosure of assets and liabilities at the date of the consolidated financial statements and the reported amounts and disclosure of revenue and expenses during the reporting period.  Actual results could differ from those estimates.

Cash Equivalents

Cash Equivalents

Cash equivalents include short-term, highly liquid investments, which consist principally of United States government and agency securities, purchased with remaining maturities of 90 days or less, and money market accounts.

Restricted Cash

Restricted Cash

Restricted cash consists of cash balances held as collateral for outstanding letters of credit related to the lease of the Company’s laboratory and office facility and other purposes.

Property and Equipment

Property and Equipment

Property and equipment are recorded at cost.  Depreciation is recorded using the straight-line method over the estimated useful lives of the assets (3 to 10 years).  Leasehold improvements and assets under capital leases are amortized over the shorter of their useful lives or lease term using the straight-line method.

Intangible and Other Assets

Intangible and Other Assets

Intangible and other assets consist primarily of purchased technology and capitalized patent and license costs.  The cost of purchased technology, patents and patent applications, costs incurred in filing patents and certain license fees are capitalized.  Capitalized costs related to purchased technology are amortized over the estimated useful life of the technology.  Capitalized costs related to issued patents are amortized over a period not to exceed seventeen years or the remaining life of the patent, whichever is shorter, using the straight-line method.  Capitalized license fees are amortized over the periods to which they relate.  In addition, capitalized costs are expensed when it becomes determinable that the related patents, patent applications or technology will not be pursued.

Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

The Company reviews its long-lived assets, including the above-mentioned intangible assets, for impairment when events or changes in circumstances indicate that the carrying amount of a long-lived asset may not be recoverable.  Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset.  If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets.

Accrued Rent

Accrued Rent

The Company recognizes rent expense for leases with increasing annual rents on a straight-line basis over the term of the lease.  The amount of rent expense in excess of cash payments is classified as accrued rent.  Any lease incentives received are deferred and amortized over the term of the lease.  At December 31, 2011, other liabilities on the balance sheet include accrued rent of $1.7 million.

Revenue Recognition

Revenue Recognition

The Company generates revenue from license and collaboration agreements with third parties related to use of the Company’s technology and/or development and commercialization of product candidates.  Such agreements may provide for payment to the Company of up-front payments, periodic license payments, milestone payments and royalties.

Revenue is recognized when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed and determinable and collection is reasonably assured.  Revenue arrangements with multiple elements are divided into separate units of accounting if certain criteria are met, including whether the delivered element has stand-alone value to the customer.  When deliverables are separable, consideration received is allocated to the separate units of accounting based on the relative selling price of each deliverable and the appropriate revenue recognition principles are applied to each unit.

The Company also generates service revenue from license agreements with third parties related to internal services provided under such agreements.  Service revenue is recognized as the services are delivered.

Income Taxes

Income Taxes

The Company accounts for income taxes using an asset and liability approach to financial accounting and reporting for income taxes.  Deferred income tax assets and liabilities are computed annually for differences between the financial statement basis and the income tax basis of assets and liabilities that will result in taxable or deductible amounts in the future.  Such deferred income tax computations are based on enacted tax laws and rates applicable to the years in which the differences are expected to affect taxable income.  A valuation allowance is established when it is necessary to reduce deferred income tax assets to the amount that is considered to be more-likely-than-not realizable.

The Company does not recognize a tax benefit unless it is more likely than not that the tax position will be sustained upon examination, including resolution of any related appeals or litigation processes, based on the technical merits of the position.  The tax benefit that is recorded for these positions is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement.

Segment Reporting

Segment Reporting

The Company organizes itself into one operating segment reporting to the chief executive officer.

Stock-Based Compensation

Stock-Based Compensation

The Company awards stock options and other equity-based instruments to its employees, directors and consultants and provides employees the right to purchase common stock (collectively “share-based payments”), pursuant to stockholder approved plans.  Compensation cost related to such awards is measured based on the fair value of the instrument on the grant date and is recognized on a straight-line basis over the requisite service period, which generally equals the vesting period.

Executive Compensation Plan

Executive Compensation Plan

The Company has an unfunded deferred executive compensation plan that defers the payment of annual bonus awards to officers to future periods as specified in each award.  The value of the awards is indexed to the value of specified mutual funds.  The Company accrues a liability based on the value of the awards ratably over the vesting period (generally four years).  The recorded balances of such awards are increased or decreased based on the actual total return and quoted market prices of the specified mutual funds.

Subsequent Events

Subsequent Events

The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

In April 2010, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2010-17, Revenue Recognition - Milestone Method, which provides guidance on determining whether a milestone is substantive including the criteria that must be met for a milestone to be considered a substantive milestone and the recognition of consideration received upon achievement of a substantive milestone.  ASU No. 2010-17 is effective for fiscal years, and interim periods within those fiscal years, beginning on or after June 15, 2010.  The Company adopted this ASU on January 1, 2011 with no material impact on its financial statements.

In October 2009, the FASB issued authoritative guidance that modifies the accounting for multiple element revenue arrangements.  This guidance requires an entity to allocate revenue to each unit of accounting in multiple deliverable arrangements based on the relative selling price of each deliverable.  It also changes the level of evidence of stand-alone selling prices required to separate deliverables by requiring an entity to make its best estimate of the stand-alone selling price of the deliverables when more objective evidence of selling price is not available.  This guidance is effective for fiscal years beginning after June 15, 2010 and may be applied prospectively to new or materially modified arrangements after the effective date or retrospectively.  The Company adopted this guidance on January 1, 2011 and although the adoption did not materially impact its financial condition, results of operations, or cash flows, this guidance may impact the Company’s determination of the separation of deliverables for future arrangements.

In June 2011, the FASB issued ASU No. 2011-05, Presentation of Comprehensive Income, which requires the presentation of other comprehensive income in either a continuous statement of comprehensive income or in two separate but consecutive statements.  ASU No. 2011-05 is effective for fiscal years, and interim periods within those fiscal years, beginning on or after December 15, 2011 and requires retrospective application.  This guidance will require a change in the presentation of the financial statements, however it will not have a material impact unless the Company has components of other comprehensive income other than net income (loss).

XML

Stock-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2011

Total Compensation Cost from Share-Based Payments

The Company’s statement of operations included total compensation cost from share-based payments for the years ended December 31, as follows:

In thousands	2011		2010		2009
Compensation cost from:
Stock options	$	2,893	$	1,879	$	3,068
Stock and stock units		4,601		2,834		1,096
Purchases of common stock at a discount		181		123		191
	$	7,675	$	4,836	$	4,355
Compensation cost included in:
Research and development expenses	$	3,782	$	2,444	$	2,123
General and administrative expenses		3,893		2,392		2,232
	$	7,675	$	4,836	$	4,355

Summary of Information About Stock Options

The following table summarizes information about stock options as of and for the years ended December 31, 2011, 2010 and 2009:

In thousands, except per share amounts	2011		2010		2009
Weighted average fair value of options granted, per share	$	5.80	$	2.43	$	1.03
Total cash received from exercises of stock options		4,648		418		206
Total intrinsic value of stock options exercised		5,169		331		271

Weighted-Average Assumptions of Fair Value of Options Granted

The weighted average fair value of options granted in the years ended December 31, 2011, 2010 and 2009, reflect the following weighted-average assumptions:

	2011		2010		2009
Expected life of options granted (in years)	7.48		6.75		7.04
Expected volatility	74.77	%	78.54	%	70.68	%
Risk-free rate	2.53	%	2.57	%	2.75	%
Expected dividends	0	%	0	%	0	%

Summary of Stock-Based Activity

Stock option activity under the Company’s stock plans for the year ended December 31, 2011 was as follows:

	Number of Shares		Weighted Average Exercise Price Per Share
Options outstanding, January 1, 2011		7,177,191	$	4.42
Granted		1,599,519	$	8.05
Forfeited		225,295	$	4.16
Exercised		1,170,086	$	4.40
Options outstanding, December 31, 2011		7,381,329	$	5.22

Summary of Stock Options Outstanding

The following table summarizes information about stock options outstanding as of December 31, 2011:

	Options Outstanding		Options Exercisable		Options Vested and Expected To Vest
Number of options		7,381,329		5,055,872		7,066,555
Weighted average exercise price per share	$	5.22	$	4.84	$	5.21
Aggregate intrinsic value (in 000’s)	$	51,878	$	37,468	$	49,717
Weighted average remaining contractual term	5.52 years		4.07 years		5.38 years

Stock and Stock Units Grants [Member]

Summary of Stock-Based Activity

Stock and stock unit activity under the Company’s stock plans for the year ended December 31, 2011 was as follows:

	Number of Shares		Weighted Average Grant Date Fair Value
Outstanding, January 1, 2011		2,779,300	$	2.83
Granted		1,255,681	$	7.43
Forfeited		115,632	$	4.05
Vested or restrictions lapsed		1,134,323	$	3.69
Outstanding, December 31, 2011		2,785,026	$	4.51

XML

Stock Option Activity Under Stock Plans (Detail) (USD $)	12 Months Ended
	Dec. 31, 2011
Number of Shares
Options outstanding, beginning of year	7,177,191
Granted	1,599,519
Forfeited	225,295
Exercised	1,170,086
Options outstanding, end of year	7,381,329
Weighted Average Exercise Price Per share
Options outstanding, beginning of year	$ 4.42
Granted	$ 8.05
Forfeited	$ 4.16
Exercised	$ 4.40
Options outstanding, end of year	$ 5.22

XML

Stockholders Equity and Warrants- Narrative (Detail) (USD $)	1 Months Ended				12 Months Ended
	Dec. 31, 2011	Oct. 31, 2010	Aug. 31, 2009	Feb. 28, 2009 Right	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Oct. 29, 2011	Jan. 21, 2010
Stockholders Equity Note [Line Items]
Preferred stock, authorized	10,000,000				10,000,000	10,000,000
Common stock, authorized	240,000,000				240,000,000	240,000,000
Issuance of common stock, net of issuance costs (in shares)	24,725,000	16,000,000	21,850,000	14,378,698
Shares of common stock issued upon exercise by the underwriters of their over-allotment option			2,850,000
Common stock issuance price	$ 10.42	$ 3.7	$ 1.75	$ 1.69	$ 10.42
Issuance of common stock, net of issuance costs	$ 243,058,000	$ 57,515,000	$ 35,600,000	$ 22,800,000	$ 243,058,000	$ 57,515,000	$ 58,370,000
Warrants issued				10,784,024
Exercise price of warrants				2.15
Issuance of common stock from warrant exercise					3,757,767	1,220,414
Warrants exercise date				Aug. 25, 2009
Warrants expiration date				2012-02-25
Proceeds from issuance of common stock pursuant to warrants					8,080,000	2,624,000
Adjustment of additional paid-up capital up on exercise of warrants					25,000,000	4,700,000
Warrants outstanding, rights	5,805,843				5,805,843
Warrants outstanding, value	12,500,000				12,500,000
Shelf registration statement, total value									125,000,000
Shelf registration statement, remaining value								$ 65,800,000

XML

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (USD $) In Thousands, except Share data, unless otherwise specified	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Beginning Balance at Dec. 31, 2008	$ (69,198)	$ 71	$ 369,313	$ 18	$ (438,600)
Beginning Balance (in shares) at Dec. 31, 2008		71,365,339
Issuance of shares pursuant to ARIAD stock plans (in shares)		995,893
Issuance of shares pursuant to ARIAD stock plans	568	1	567
Issuance of shares to minority shareholders of AGTI (in shares)		452,852
Issuance of shares to minority shareholders of AGTI	474	1	473
Issuance of common stock, net of issuance costs (in shares)		36,228,698
Issuance of common stock, net of issuance costs	58,370	36	58,334
Issuance of warrants	(3,559)		(3,559)
Stock-based compensation	4,355		4,355
Comprehensive (loss) income:
Net (loss) income	(80,008)				(80,008)
Net unrealized losses on marketable securities	(18)			(18)
Total comprehensive (loss) income	(80,026)
Ending Balance at Dec. 31, 2009	(89,016)	109	429,483		(518,608)
Ending Balance (in shares) at Dec. 31, 2009		109,042,782
Issuance of shares pursuant to ARIAD stock plans (in shares)		679,235
Issuance of shares pursuant to ARIAD stock plans	789	1	788
Issuance of common stock, net of issuance costs (in shares)		16,000,000
Issuance of common stock, net of issuance costs	57,515	16	57,499
Issuance of common stock from warrant exercise (in shares)	1,220,414	1,220,414
Issuance of common stock from warrant exercise	4,704	1	4,703
Stock-based compensation	4,836		4,836
Comprehensive (loss) income:
Net (loss) income	85,248				85,248
Total comprehensive (loss) income	85,248
Ending Balance at Dec. 31, 2010	64,076	127	497,309		(433,360)
Ending Balance (in shares) at Dec. 31, 2010		126,942,431
Issuance of shares pursuant to ARIAD stock plans (in shares)		2,183,504
Issuance of shares pursuant to ARIAD stock plans	4,791	2	4,789
Issuance of common stock, net of issuance costs (in shares)		24,725,000
Issuance of common stock, net of issuance costs	243,058	25	243,033
Issuance of common stock from warrant exercise (in shares)	3,757,767	3,757,767
Issuance of common stock from warrant exercise	24,971	4	24,967
Stock-based compensation	7,675		7,675
Payments of tax withholding obligations related to stock compensation	(827)		(827)
Comprehensive (loss) income:
Net (loss) income	(123,603)				(123,603)
Total comprehensive (loss) income	(123,603)
Ending Balance at Dec. 31, 2011	$ 220,141	$ 158	$ 776,946		$ (556,963)
Ending Balance (in shares) at Dec. 31, 2011		157,608,702

XML

Intangible and Other Assets, Net

12 Months Ended

Dec. 31, 2011

Intangible and Other Assets, Net

4.     Intangible and Other Assets, Net

Intangible and other assets, net, were comprised of the following at December 31:

In thousands	2011			2010
Capitalized patent and license costs	$	6,799		$	6,465
Purchased technology		5,901			5,901
		12,700			12,366
Less accumulated amortization		(6,957	)		(5,332	)
		5,743			7,034
Other assets		42			38
	$	5,785		$	7,072

Amortization expense for intangible assets amounted to $1.7 million, $0.9 million and $1.0 million in 2011, 2010 and 2009, respectively.  The weighted average amortization period for intangible assets was 14.9 years, 14.8 years and 15.2 years in 2011, 2010 and 2009, respectively.  The estimated future amortization expense is $470,000 for 2012 and $435,000 per year for 2013, 2014, 2015, 2016 and $3.5 million thereafter.

For the years ended December 31, 2011, 2010 and 2009, the Company recorded charges in research and development expense of $312,000, $2.4 million and $47,000, respectively, to reflect impairment of the carrying value of certain capitalized patents and licenses.  In 2010, the charges relate to the write-off of the carrying value of patents related to the Company’s NF-кB technology, upon unsuccessful conclusion of litigation related to this technology, and an impairment of the carrying value of the ARGENT patents and certain other patents based on an assessment of future cash flows anticipated from these technologies.

XML

Income Taxes - Narrative (Detail) (USD $) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Income Tax Contingency [Line Items]
Deferred tax assets valuation allowance increased	$ 28.5	$ (43.5)	$ 21.9
Recognized tax benefit from net operating loss carryforwards, federal		7.9
Recognized tax benefit from net operating loss carryforwards, state		$ 1.4

XML

Net Income (Loss) Per Share (Tables)

12 Months Ended

Dec. 31, 2011

Calculation of Net Income (Loss) and the Number of Shares Used to Compute Basic and Diluted Earnings per Share

The calculation of net income (loss) and the number of shares used to compute basic and diluted earnings per share for the years ended December 31, 2011, 2010 and 2009 are as follows:

In thousands	2011			2010		2009
Net income (loss)	$	(123,603	)	$	85,248	$	(80,008	)
Weighted average shares outstanding - basic		132,375			113,020		93,330
Dilutive stock options		---			572		---
Restricted stock and restricted stock units		---			1,142		---
Weighted average shares outstanding ­- diluted		132,375			114,734		93,330

Potentially Dilutive Securities Excluded in the Computation of Net Income (Loss) Per Share

For the years ended December 31, 2011, 2010 and 2009, the following potentially dilutive securities were not included in the computation of net income (loss) per share because the effect would be anti-dilutive:

In thousands	2011		2010		2009
Stock options		7,381		5,852		7,684
Restricted stock and restricted stock units		2,785		---		1,489
Warrants		5,806		9,564		10,784
		15,972		15,416		19,957

XML

Long-term Debt and Capital Lease Obligations (Future Scheduled Principal Payments Due Under Financing Obligations) (Detail) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2011	Dec. 31, 2010
Debt Instrument [Line Items]
Future scheduled principal payments under bank term loan due 2012	$ 1,400
Future scheduled principal payments under bank term loan due 2013	2,100
Future scheduled principal payments under bank term loan due 2014	4,200
Future scheduled principal payments under bank term loan due 2015	4,900
Bank term loan	12,600	9,625
Less current portion	(1,400)
Bank term loan, long-term portion	11,200
Future scheduled principal payments under capital lease due 2012	54
Future scheduled principal payments under capital lease due 2013	15
Future scheduled principal payments under capital lease due 2014
Future scheduled principal payments under capital lease due 2015
Capital lease obligations	69
Less current portion	(54)
Capital leases obligations, long-term portion	$ 15

XML

Related Party Transaction

12 Months Ended

Dec. 31, 2011

Related Party Transaction

14.   Related Party Transaction

In the offering and sale by the Company of 21,850,000 shares of its common stock on August 7, 2009 (see Note 8), the Company's chief executive officer purchased 1,714,286 shares, at the offering price of $1.75 per share, for $3 million.